Drug intelligence / Profile preview

APZ004

Development stage: Preclinical
Lead developer: AMPO Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

APZ004 is a monoclonal antibody biosimilar developed by Foshan Ampze Biopharma (Annpobio) that targets the CD20 antigen. It is being developed as a biosimilar to rituximab (Rituxan/MabThera) for the treatment of hematological diseases, including non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). By binding to CD20 on the surface of B-lymphocytes, the drug mediates B-cell depletion through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis. The program is currently in the preclinical stage of development, focusing on hematological malignancies and potentially autoimmune conditions.

Other names: rituximab biosimilar

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on APZ004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APZ004.

Explore the full profile